Please login to the form below

Not currently logged in
Email:
Password:

Generic Zyprexa launched in US

Teva Pharmacuetical and Dr Reddy's have had a generic version of Eli Lilly & Company's blockbuster schizophrenia drug Zyprexa (olanzapine) approved by the US Food and Drug Administration

Teva Pharmacuetical and Dr Reddy's have had a generic version of Eli Lilly & Company's blockbuster schizophrenia drug Zyprexa (olanzapine) approved by the US Food and Drug Administration (FDA).

It is the first generic olanzapine product to be marketed in the US. Lilly's Zyprexa is one of the biggest-selling drugs affected by the patent cliff, achieving global sales of $5.03bn in 2010.

Lilly has already seen the first affects of generic competition for Zyprexa in its financial results for the third quarter of 2011, with sales down 3 per cent for the period.

Teva's olanzapine tablets in 2.5mg, 5mg, 7.5mg, 10mg and 15mg doses and Dr Reddy's olanzapine tablets in 20mg doses have each been awarded a 180-day period of marketing exclusivity in the US, following an agreement made between the two companies in April 2011.

In addition, Dr Reddy's will launch its 2.5mg, 5mg, 7.5mg, 10mg ,15mg and 20mg of olanzapine tablets upon expiration of the 180-day exclusivity period.

Dr Keith Webber, deputy director of the Office of Pharmaceutical Science in the FDA's Center for Drug Evaluation and Research, said: "The approval of generic olanzapine offers greater access to a widely used treatment for mental illnesses. Having affordable treatment options is good for patients with long-term illnesses that must be carefully managed."

25th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics